What you should know:
1. Takeda wants to make 1.5 billion euros — $1.68 billion — from the sale.
2. The portfolio consists of over-the-counter and prescription medications where Takeda’s patent has expired. Despite that, the portfolio has an EBITDA of around 160 million euros ($179.6 million).
3. Takeda retained the services of JPMorgan to find a buyer.
4. Takeda’s acquisition of Shire put the company $52.73 billion in debt. To lower this, Takeda is attempting to sell $10 billion in assets.
More articles on surgery centers:
6 surgery centers achieving total joint milestones
Regent Surgical Health, Conformis partner to cut ASC joint replacement costs
ASC total joint program bundles, vendors & more — 3 insights from an administrator
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
